Most advanced and fastest growing cannabis market in the world.
World leader in cannabis and cannabinoid R&D
SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system.
SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life- threatening conditions that present a high level of unmet need.
SciCann Therapeutics holds a diversified portfolio of IP and ownerships in ventures operating in the cutting edge technology of cannabinoid science, and maintains a wide network of strategic and synergistic collaborations with leading research institutes and commercial companies in the space.
Rational for operating in the cannabinoid pharmaceutical space
The Cannabis plant contains over 400 pharmaceutically active compounds, most of which have never been studied for their profound therapeutic effects.
Recent studies suggest that unique and synergistic cannabinoid combinations may have a high therapeutic potential in almost all diseases affecting humans, including cancer, neurodegenerative diseases, auto-immune disorders, and many more.
Experts estimate that cannabinoid based drugs can replace up to 30%-40% of existing prescription drug consumption in the near future.
SciCann Therapeutics is dedicated to the discovery and development of novel and proprietary technologies in the cannabinoid space, including new therapeutic agents, drug candidates, novel cannabis genetics, personalized treatment tools and more.
R&D in Israel – Commercialization in Canada
R&D in Israel – Commercialization in Canada
SciCann Therapeutics is bridging the gap between Israel’s strong R&D capabilities in the field of cannabinoid science and Canada’s booming medical cannabis markets.
SciCann Therapeutics is collaborating with Israel’s leading research labs and medical centers, and commercializing its resulting innovative and proprietary products in leading international markets, focusing initially on the strong medical cannabis market in Canada.
Sheldon Inwentash B.Comm., CA., CPA., LL.D.
Serial entrepreneur, chairman and chief executive officer of ThreeD Capital Inc., a Toronto-based venture capital firm specializing in investments in junior resources, technology and biotechnology.
co-founded Visible Genetics, the first commercial pharmacogenomics company, in 1994 and exited in 2001 to Bayer Through two decades leading Pinetree Capital, Mr. Inwentash created significant shareholder value through early investments in Queenston Mining (acquired by Osisko Mining Corp. for $550 million), Aurelian Resources (acquired by Kinross for $1.2 billion), and Gold Eagle Mines (acquired by Goldcorp for $1.5 billion) to name a few.
In 2012 Mr. Inwentash received an honorary degree, doctor of laws (LLD) from the University of Toronto for his valuable leadership as an entrepreneur and philanthropist.
Zohar Koren, PhD
An experienced entrepreneur and inventor in the pharmaceutical and medical cannabis fields.
Co-founder, director and CEO of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of novel medical cannabis formulations and products, established in 2012.
VP BD of Mor Research applications – the commercial arm of Clalit Healthcare Services.
Director of BD at Aposense Ltd (TASE:APOS) – a speciality pharma company in the oncology field.
Veteran of the prestigious IDF Talpiyot project, holds a PhD in the fields of molecular and computational biology.
Daniel N. Bloch, B.Comm., LL.B.
VP BD and General Counsel
An expert in international corporate finance, mergers and acquisitions, joint ventures, private equity and securities law.
member of the Law Society of Canada and a registered Foreign Lawyer with the Israeli Bar Association.
Served as an officer and director of various Canadian and U.S. publicly listed companies and is a member of the Association of International Negotiators.
Canadian capital markets advisor
Founder and CEO of Rivonia Capital, a Canadian finance and capital markets advisory firm specializing in the cannabis space.
Co-founder of capital pool corporation, which took the Cronos Group public into the TSXV.
Prof. Dan Peer
Head of Scientific Advisory Board
Chairman of Tel Aviv University Cancer Biology Research Center – the biggest Cancer Center in Israel that includes 17 affiliated hospitals.
Director of Israel’s national nanomedicine initiative project.
Director of Leona M. and Harry B. Helmsley Nanotechnology Research Fund.
FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston
SciCann Therapeutics Announces Positive ISA Report for “Steady Stomach” CBD Combination Therapy Patent
FSD Pharma Announces Launch of IBS Clinical Study
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product
FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel
Get In Touch
SEND US A MESSAGE
69 Yonge St. , Suite 1010
Reaching beyond the unknown boundaries of cannabinoid science
Canadian Pacific Building, 69 Yonge St, Toronto Canada